Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients - Evaluation of appropriate research design and methodology to measure symptoms

Breast Cancer

Volumn 12, Issue 4, 2005, Pages 279-287

  Matsuda, Tomohiro ^a   Takayama, Tomoko ^b   Tashiro, Manabu ^c   Nakamura, Yu ^d   Ohashi, Yasuo ^e   Shimozuma, Kojiro ^f  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF MARKETING AND DISTRIBUTION SCIENCES   (Japan)

Author keywords

Breast cancer; Chemotherapy; Cognitive impairment; PET; Qol

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; BIOASSAY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEPRESSION; FATIGUE; FEMALE; HUMAN; INTELLIGENCE; LONGITUDINAL STUDY; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; DEPRESSION; ENDPOINT DETERMINATION; FATIGUE; FEMALE; HUMANS; INTELLIGENCE; LONGITUDINAL STUDIES; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33644839308     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.2325/jbcs.12.279     Document Type: Review

References (58)

1. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701, 2000. (Pubitemid 30463551)
2. Davis BD, Fernandez F, Adams F, Holmes V, Levy JK, Lewis D, Neidhart J: Diagnosis of dementia in cancer patients. Cognitive impairment in these patients can go unrecognized. Psychosomatics 28:175-179, 1987. (Pubitemid 17059272)
3. Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL: Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 21:407-424, 2001. (Pubitemid 32452141)
4. Goodwin JS, Samet JM, Hunt WC: Determinants of survival in older cancer patients. J Natl Cancer Inst 88:1031-1038, 1996. (Pubitemid 26260488)
5. Mandelblatt J, Figueiredo M, Cullen J: Outcomes and quality of life following breast cancer treatment in older women: When, why, how much, and what do women want? Health Qual Life Outcomes 1:45, 2003.
6. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999. (Pubitemid 29075285)
7. Meyers CA, Abbruzzese JL: Cognitive functioning in cancer patients: effect of previous treatment. Neurology 42:434-436, 1992.
8. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: highdose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998. (Pubitemid 28114539)
9. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FS: Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387-1397, 2002.
10. Berglund G, Bolund C, Fornander T, Rutqvist LE, Sjoden PO: Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27:1075-1081, 1991.
11. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002. (Pubitemid 34072533)
12. Olin JJ: Cognitive function after systemic therapy for breast cancer. Oncology (Huntingt) 15:613-618; discussion 618, 621-624, 2001. (Pubitemid 33739126)
13. Harder H, Cornelissen JJ, Van Gool AR, Duivenvoorden HJ, Eijkenboom WM, van den Bent MJ: Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer 95:183-192, 2002. (Pubitemid 34743497)
14. Logsdon RG, Gibbons LE, McCurry SM, Teri L: Assessing quality of life in older adults with cognitive impairment. Psychosom Med 64:510-519, 2002. (Pubitemid 34556417)
15. Terada S, Ishizu H, Fujisawa Y, Fujita D, Yokota O, Nakashima H, Haraguchi T, Ishihara T, Yamamoto S, Sasaki K, Nakashima Y, Kuroda S: Development and evaluation of a health-related quality of life questionnaire for the elderly with dementia in Japan. Int J Geriatr Psychiatry 17:851-858, 2002.
16. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, demons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175-4183, 2003. (Pubitemid 46606186)
17. Dew MA, Kormos RL, Winowich S, Harris RC, Stanford EA, Carozza L, Griffith BP: Quality of life outcomes after heart transplantation in individuals bridged to transplant with ventricular assist devices. J Heart Lung Transplant 20:1199-1212, 2001. (Pubitemid 33036855)
18. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191-214, 1994. (Pubitemid 24118030)
19. Svane IM, Homburg KM, Kamby C, Nielsen DL, Roer O, Sliffsgaard D, Johnsen HE, Hansen SW: Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer-a quality assessment study. Acta Oncol 41:675-683, 2002. (Pubitemid 36106213)
20. van Gerven JM, Moll JW, van den Bent MJ, Bontenbal M, van der Burg ME, Verweij J, Vecht CJ: Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30 A: 1074-1077, 1994.
21. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 6:489-494, 1995.
22. Phillips KA, Bernhard J: Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95:190-197, 2003. (Pubitemid 36240631)
23. Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T: Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 9:352-363, 2000.
24. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279:688-695, 1998. (Pubitemid 28138739)
25. Haskell SG, Richardson ED, Horwitz RI: The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epidemiol 50:1249-1264, 1997. (Pubitemid 27502957)
26. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61-66, 2004. (Pubitemid 38139358)
27. Meyers CA, Byrne KS, Komaki R: Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12:231-235, 1995.
28. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA: Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90:427-432, 2002. (Pubitemid 36124778)
29. Burmeister LA, Ganguli M, Dodge HH, Toczek T, De Kosky ST, Nebes RD: Hypothyroidism and cognition: preliminary evidence for a specific defect in memory. Thyroid 11:1177-1185, 2001. (Pubitemid 34041899)
30. Peace KA, Orme SM, Thompson AR, Padayatty S, Ellis AW, Belchetz PE: Cognitive dysfunction in patients treated for pituitary tumours. J Clin Exp Neuropsychol 19:1-6, 1997. (Pubitemid 27122098)
31. McLachlan SA, Devins GM, Goodwin PJ: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. Eur J Cancer 34:510-517, 1998. (Pubitemid 28179347)
32. Cimprich B, Ronis DL: Attention and symptom distress in women with and without breast cancer. Nurs Res 50:86-94, 2001. (Pubitemid 33603795)
33. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J, Walot I, Boone K, Chlebowski R: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94:592-597, 2002. (Pubitemid 34498646)
34. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ: Estrogen-and tamoxifen-associated effects on brain structure and function. Neuroimage 21:364-371, 2004. (Pubitemid 38115027)
35. Paganini-Hill A, Clark LJ: Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165-176, 2000. (Pubitemid 32010334)
36. Ahles TA, Saykin AJ: Breast cancer chemotherapyrelated cognitive dysfunction. Clin Breast Cancer 3 Suppl 3:S84-90, 2002.
37. Bruera E, Fainsinger RL, Miller MJ, Kuehn N: The assessment of pain intensity in patients with cognitive failure: a preliminary report. J Pain Symptom Manage 7:267-270, 1992.
38. Wechsler D: WMS-R: Wechsler memory scale-revised manual., New York: The Psychological Corporation, 1987.
39. Wechsler D: Manual for the Wechsler Adult Intelligence Scale-Revised., New York: The Psychological Corporation, 1981.
40. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975.
41. Pereira J, Hanson J, Bruera E: The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 79:835-842, 1997. (Pubitemid 27076350)
42. Tang-Wai DF, Knopman DS, Geda YE, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Boeve BF, Petersen RC: Comparison of the short test of mental status and the mini-mental state examination in mild cognitive impairment. Arch Neurol 60:1777-1781, 2003. (Pubitemid 37521636)
43. Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ, Smith GE, Tangalos EG, Jack CR, Jr.: Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 61:500-506, 2003. (Pubitemid 37025367)
44. Iuvone L, Mariotti P, Colosimo C, Guzzetta F, Ruggiero A, Riccardi R: Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 95:2562-2670, 2002.
45. Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, Schmidt-Wolf I, Schlegel U: Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563-568, 2003. (Pubitemid 36427970)
46. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397-1403, 1999. (Pubitemid 29190530)
47. Tashiro M, Juengling FD, Reinhardt MJ, Mix M, Kumano H, Kubota K, Itoh M, Sasaki H, Nitzsche EU, Moser E: Depressive state and regional cerebral activity in cancer patients - a preliminary study. Med Sci Monit 7:687-695, 2001. (Pubitemid 32691747)
48. Erritzoe D, Talbot P, Frankle WG, Abi-Dargham A: Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clin N Am 13:817-832, 2003. (Pubitemid 37445058)
49. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, Grace AA, Wong DF: Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159:1329-1336, 2002. (Pubitemid 34832714)
50. Klepstad P, Hilton P, Moen J, Fougner B, Borchgrevink PC, Kaasa S: Self-reports are not related to objective assessments of cognitive function and sedation in patients with cancer pain admitted to a palliative care unit. Palliat Med 16:513-519, 2002. (Pubitemid 35386010)
51. Ahles TA, Saykin A: Cognitive effects of standarddose chemotherapy in patients with cancer. Cancer Invest 19:812-820, 2001. (Pubitemid 33151212)
52. Ganz PA: Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst 90:182-183, 1998. (Pubitemid 28114536)
53. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG: Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9 Suppl 1:65-69, 1997. (Pubitemid 28045341)
54. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-308, 1999. (Pubitemid 29120227)
55. Fisk JD, Merry HR, Rockwood K: Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology 61:1179-1184, 2003. (Pubitemid 37377534)
56. Knopman DS, Boeve BF, Petersen RC: Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 78:1290-1308, 2003. (Pubitemid 37193520)
57. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50:136-145, 1998.
58. Barton D, Loprinzi C: Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 3 Suppl 3:S121-127, 2002.